Pharmaceutical

Since 2017 we have seen the slow and steady adoption of User Experience (UX) within the life sciences. User Experience is an evidence-based design process that centres on the behaviours and needs of users. The clear benefits of UX offered in the retail and consumer sectors have been slow to percolate to other more complex […]

R&D spending in the UK pharmaceutical sector has jumped 6.9% annually to an eight-year high, analysis of the latest ONS data by R&D tax relief specialist Catax shows. Total pharmaceutical industry spending on R&D rose to £4.8bn last year, an increase of £306m from the £4.5bn recorded a year earlier1. It was the largest real-terms […]

New research from GovGrant, R&D and IP specialist, reveals that 86% of UK SMEs in health-related sectors think innovation is important for their recovery from COVID-19. Despite this, almost half (47%) – healthcare, medtech and pharma – say the cost is the main barrier for them when it comes to pursuing innovative activity. The news […]

Mike Rea, CEO of IDEA Pharma, has worked on some successful new drug and medical product launches over the last 20 years. His new book, Pharmaceutical Positioning (now available on Amazon), is he claims, the world’s first book on positioning pharmaceuticals. As a discipline, positioning emerged in the 20th century as a powerful concept in product […]

Richard Torbett, Chief Executive, ABPI says vaccines are one of our best hopes for eradicating COVID-19 and why the ABPI is launching a campaign to highlight this. “COVID-19 has put shone a spotlight on the pharmaceutical industry like never before. Millions of people all over the world are living under some form of restrictions.  The […]

CEVEC Pharmaceuticals has signed an option and license agreement with Roche for the use of its newly launched ELEVECTA Technology for large scale manufacturing of adeno‐associated virus (AAV) vectors for gene therapy applications. Under the terms of the agreement, CEVEC will grant Roche, and Spark Therapeutics, a member of the Roche Group, an option for […]

Non-alcoholic fatty liver disease (NAFLD) has quietly become one of the most common causes of chronic liver disease in the modern world. If this prevalence is allowed to continue the economic and clinical burden will reach a staggering level. Non-alcoholic fatty liver disease (NAFLD) consists of a complex combination of liver maladies, ranging from benign […]

GSK has announced ambitious new environmental sustainability goals in both climate and nature, aiming to have a net zero impact on climate and a net positive impact on nature by 2030. The new goals form part of GSK’s Trust priority and ESG approach, which support the company’s aim to create long-term value for shareholders and […]

4D pharma, a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) – a novel class of drug derived from the microbiome – and Longevity Acquisition a NASDAQ-listed Special Purpose Acquisition Company (SPAC), have announced a proposed merger. The deal is worth up to $37.6 million to 4D pharma. As a result of the […]

This article will describe, with examples, how understanding the likely mechanisms of false positives in advance of screening informs the design of the hit triage, thus increasing the likelihood of discovering optimisable chemical matter and avoiding costly wasting of resource. We describe the use of a bespoke ‘Robustness Set’ of nuisance compounds and how it […]